Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

5 passive income stocks I’d buy right now

To me, a stock suitable for generating passive income will be backed by a big business capable of paying enduring shareholder dividends, such as these.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I like the idea of buying passive income stocks and holding them for the long term.

To me, a stock suitable for generating passive income will be backed by a big business capable of paying enduring shareholder dividends.

I could hold the shares and take the dividends as passive income. Or I could roll the dividends back into my investments to help compound my gains.

My preferred passive income stocks

Some of my preferred choices have seen weaker share prices lately. So I reckon it’s a good time for me to run the calculator over those investment opportunities.

For example, in the pharmaceutical sector, I like the look of AstraZeneca and GlaxoSmithKline. Both companies have steady underlying businesses that tend to keep on generating cash flow whatever the general economic weather. And that’s because people tend to prioritise purchasing medicines, however tough the times.

With its share price near 1,325p, GlaxoSmithKline’s forward-looking dividend yield is just below 5% for 2022. However, the company plans to split its operations into standalone Biopharma and Consumer Healthcare companies in 2022. Those plans are creating some uncertainty and the forward yield is set to drop a little because of the change. On top of that, the share price has been trending lower since the beginning of 2020 and that move could continue.

Meanwhile, with AstraZeneca’s share price near 7,494p, the forward-looking dividend yield for 2022 is around 2.8%. That’s quite a modest yield and there’s some risk the valuation could contract. That might happen if the rate of earnings growth declines, for example. Nevertheless, I’m tempted to buy shares in both firms for a long-term portfolio focused on passive income.

Branded fast-moving consumer goods

In the fast-moving-consumer-goods space, I’m keen on Reckitt Benckiser and Unilever. The companies’ ranges of branded food, cleaning and hygiene products tend to sell consistently as medicines do in the pharmaceutical sector. People love to keep buying their ‘essentials’ in good times and bad, and that tends to lead to solid and reliable cash inflow.

With the share price near 6,676p, Reckitt Benckiser’s forward-looking dividend yield for 2022 is just below 2.7%. And at 4,128p, Unilever’s is just over 3.6%. Both of those income streams have a multi-year history of incremental annual growth.

However, I’d describe the valuation of both companies as rich. And there’s a possibility the shares will move lower so that the valuation becomes fairer. If that happens, I could lose money on my holdings. Nevertheless, I’d put these two stocks in my passive income portfolio to hold for the long term.

My final passive income pick is energy transmission system provider National Grid. I see the firm’s regulated monopoly position in the UK’s energy network as attractive. And the sector is defensive and less prone to cyclical ups and downs than many others. There’s also a business in the US.

With the share price near 911p, the forward-looking dividend yield for the trading year to March 2022 is just below 5.5%. I think that’s attractive but National Grid carries a lot of debt, which could combine with regulatory changes in the future to threaten shareholder payments. Nevertheless, I’d add this one to my passive income portfolio.

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has recommended GlaxoSmithKline and Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

The BP share price could face a brutal reckoning in 2026

Harvey Jones is worried about the outlook for the BP share price, as the global economy struggles and experts warn…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

How on earth did Lloyds shares explode 75% in 2025?

Harvey Jones has been pleasantly surprised by the blistering performance of Lloyds shares over the last year or two. Will…

Read more »

Group of four young adults toasting with Flying Horse cans in Brazil
Investing Articles

Down 56% with a 4.8% yield and P/E of 13 – are Diageo shares a generational bargain?

When Harvey Jones bought Diageo shares he never dreamed they'd perform this badly. Now he's wondering if they're just too…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

Could these 3 holdings in my Stocks and Shares ISA really increase in value by 25% in 2026?

James Beard’s been looking at the 12-month share price forecasts for some of the positions in his Stocks and Shares…

Read more »

National Grid engineers at a substation
Investing Articles

2 reasons I‘m not touching National Grid shares with a bargepole!

Many private investors like the passive income prospects they see in National Grid shares. So why does our writer not…

Read more »

Number 5 foil balloon and gold confetti on black.
Investing Articles

£10,000 invested in Greggs shares 5 years ago would have generated this much in dividends…

Those who invested in Greggs shares five years ago have seen little share price growth. However, the dividends have been…

Read more »

Rolls-Royce Hydrogen Test Rig at Loughborough University
Growth Shares

Here is the Rolls-Royce share price performance for 2023, 2024, and 2025

Where will the Rolls-Royce share price be at the end of 2026? Looking at previous years might help us find…

Read more »

Investing Articles

This FTSE 250 stock could rocket 49%, say brokers

Ben McPoland takes a closer look at a market-leading FTSE 250 company that generates plenty of cash and has begun…

Read more »